IPM Take
England’s National Cancer Plan is important because it treats personalised cancer care as a full pathway, not just access to targeted medicines. It connects prevention, earlier diagnosis, genomic testing, digital tools, AI-assisted diagnostics, clinical trials, personalised support and survivorship. That is the right ambition. The harder question is whether the NHS can deliver this consistently across regions, workforce pressures and local service gaps, so personalised care does not remain strongest only in better-resourced centres.
Executive Summary
The UK government published the National Cancer Plan for England on 4 February 2026 and updated the accessible version in April 2026. The plan aims for 3 in every 4 people diagnosed in 2035 to be cancer-free or living well with cancer after five years, compared with a projected 60% in 2022. It commits to national lung cancer screening rollout by 2030, broader genomic testing, NHS App-enabled cancer care, personalised risk profiles, digital patient-reported outcome measures, improved trial access, AI-assisted analysis of chest X-rays and pathology, and stronger attention to rare cancers and children’s cancers.
Why it matters
- Hospitals / providers: Need to prepare for a more digital, genomics-enabled cancer pathway, including timely testing, referral, data use and patient follow-up.
- Diagnostics / pathology: Must scale genomic testing, AI-supported diagnostics and turnaround capacity so results are available early enough to guide care.
- Patients / advocates: Should watch whether the plan reduces regional and social inequalities, especially for rare cancers, children’s cancers, poorer communities and ethnic minority groups.
Until now, many cancer strategies have treated innovation as separate pieces: screening in one place, genomic testing in another, treatment access elsewhere and survivorship support after that. England’s new plan tries to connect these pieces into a more personalised cancer pathway.
The change is not only clinical. By 2028, the NHS App is expected to become the front door for cancer care, helping patients manage screening invitations, appointments and treatment plans. By 2035, the plan says it should bring together genomic and lifestyle data with the single patient record to provide personalised risk profiles and prevention advice. The plan also promises broader genomic testing so that patients who need a genomic result for treatment receive it in time to affect care.
The eligibility logic is broad. This is not limited to one cancer type, one test or one medicine. It affects people at risk of cancer, newly diagnosed patients, patients needing genomic testing, people entering trials, patients living after treatment and groups historically underserved by cancer research.
The implementation question is whether England can turn this into routine delivery. Digital tools, genomics and AI will not fix access by themselves. They require workforce capacity, interoperable records, clear referral pathways, timely diagnostics and local services able to support patients after treatment. If delivered well, the plan could become a model for personalised cancer care at system scale. If not, it risks widening the gap between centres that can modernise quickly and those still struggling with basic performance.
